Business

Eli Lilly says obesity drug helped boost weight loss to 26%, highest seen in late-stage trials

The data bolsters Eli Lilly’s position in the budding weight loss drug market and establishes the company as a formidable competitor to Novo Nordisk.

Previous post Shein says it was profitable in the first half of the year as U.S. IPO rumors swirl
Next post : Natural-gas futures extend losses after EIA reports a modest weekly rise in U.S. supplies

More Stories